
Opinion|Videos|December 25, 2024
Cost Considerations for LDL Reduction Therapies
Key Takeaways
- Pediatric lipid screening is vital for early dyslipidemia detection, reducing future cardiovascular disease risk.
- Guidelines suggest universal screening at ages 9-11 and 17-21, with selective screening for at-risk children.
Panelists discuss how LDL-C management strategies must be carefully adapted for patients with immunodeficiencies, considering their unique health challenges and potential treatment interactions.
Advertisement
Episodes in this series

Video content above is prompted by the following:
- When developing strategies for LDL-C management, what considerations should be given to immunodeficiencies?
Advertisement
Latest CME
Advertisement
Advertisement
Trending on HCPLive
1
The HCPFive: Top News for Healthcare Providers from the Week of 07/12
2
Millions of New Patients Eligible for Statins Under 2026 AHA/ACC Guidelines
3
Sonnenberg Breaks Down EMERGE Phase 3 Trial Design for DT120 in MDD
4
Total Plaque Volume Indicates Patients With 0 CAC May Still be at Risk
5












































































